EMcision International Inc., a Montreal-based company specializing in advanced radiofrequency-based medical devices used in surgery, is pleased to announce it has sold its first units of the Habib™ RF DUO 13 catheter - a new device with immense potential to help abdominal cancer patients.

The Habib™ RF DUO 13 is a long, thin tube that sends electric pulses to destroy malignant cells. The device is currently approved for sale in Europe and China and the first batch was sold in recent days to medical professionals in those markets.

"The RF DUO 13 is groundbreaking and has real potential to improve the lives of those suffering from pancreatic cancer. We are honoured that top international surgeons have decided to begin a trial period with our minimally-invasive product," said Cherif Habib, CEO of EMcision.

The units sold to date will be used to treat more than 40 patients. Further shipments are planned in the coming weeks. The company hopes that the catheter will prolong the lives of cancer patients, but further clinical evidence is required.

"We look forward to working in close collaboration with our new partners to continue developing the RF DUO 13 and to expanding its reach," Mr. Habib concluded.

About EMcision

EMcision was founded by internationally renowned surgeon and inventor of medical devices, Professor Nagy Habib, to develop proprietary medical devices based on proven RF technology for the surgical community. Devices for endoscopists and interventional radiologists soon followed. In 2002, EMcision developed the Habib™ 4X for the treatment of liver cancer, which has the reputation of being the #1 hepatic resection device in the U.S. The company combines scientific, commercial and management skills, brought together in a working partnership to develop and commercialize medical devices that are clinically relevant, cost-effective and enhance the quality of life of cancer patients. EMcision's R&D, engineering and commercialization operations are based in Montreal, and clinical activities are based at the Imperial College London (U.K.) and Hammersmith Hospital.


AuthorCherif Habib